Anakinra Manages ICANS/CRS Toxicity Induced by CAR T-Cell Therapy - Targeted Oncology

Nicolas Gazeau discusses a retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who have received chimeric antigen receptor T-cell therapy.

Nicolas Gazeau, MS, postdoctoral research scholar at Fred Hutchinson Cancer Center, discusses a retrospective study of anakinra (Kineret) for the management of neurotoxicity and cytokine release synd… [+2291 chars]

full article...